STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on track in building its first ultramodern laboratory at Campus Solna, Sweden, next to world-leading healthcare.
“We signed a five-year leasing contract for our office and laboratory facilities at Campus Solna. These will be Inify’s headquarters, housing our first laboratory as well as our Center of Excellence,” says CEO Fredrik Palm at Inify.
The company expects to move into the new facility during the fourth quarter of 2022 and to immediately commence installation of systems and equipment, followed by accreditation. The laboratory will begin production of prostate cancer diagnoses according to plan – sometime during the first half of 2023.
Specially designed IT system
In parallel, Inify continues to develop and integrate a specially designed IT system and process, built to support a fully digital, standardized workflow and reporting system.
“This will enable us to provide rapid and predictable response times, while ensuring the highest possible diagnostic quality by combining our high-performing AI solution with the expertise of certified pathologists,” says Palm.
The company currently has 16 employees, supported by specialized consultants for certain tasks. In addition to a commercial team focused on mapping the potential customer base, the company is staffed with advanced technical, laboratory and medical competence; all have extensive expertise, both within their niche as well as in the pathology domain.
“Our new Chief Medical Officer, Dr. Claes Lindh, who is both a Doctor in Medicine and has a Ph.D. in prostate cancer pathology from Karolinska Institute, will join us in September. Dr. Lindh will be instrumental in the diagnostic parts of the operations, as well as our medical strategy going forward,” says Palm.
Funding
The Company raised NOK 150 million in a private placement during the second quarter, securing funding until proof-of-concept stage.
“The placement drew great interest, and we see the trading activities that took place immediately after listing as clear proof of interest for the company among investors, despite the present geo-political situation hitting the markets hard,” says Palm.
For further information, please contact CEO, Fredrik Palm, , or visit www.inify.com.
###
About Inify Laboratories
Inify Laboratories provides cancer diagnostics through ultra-modern laboratory services within histopathology. Fully digital, standardized and AI- supported workflow is applied to optimize quality and response times, initially for prostate cancer. The concept is scalable and extendible to other diagnosis. The company origins from ContextVision and became independent in February 2022.
The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Attachment
View attachment